Since 2004, cases of "chronic leukemia" have been recorded in Kyrgyzstan, and currently, there are over 500 patients, 90% of whom are adults and 10% are children. Egenberdieva noted that the delivery of the drug "Gleevec" is carried out by a European fund, while the National Center for Oncology and Hematology acts as the official partner of the humanitarian program.
According to the deputy, patients take this medication for their entire lives.
She also highlighted that residents of the southern regions have to travel to Bishkek every month to obtain the medication, which incurs significant transportation and accommodation costs—ranging from 15,000 to 20,000 soms. Patients are forced to stand in lines, go through paperwork, and sometimes wait for the medication in the capital for up to a week.
Egenberdieva proposed organizing the distribution of "Gleevec" in the Osh, Jalal-Abad, and Batken regions, transferring the medication to the Osh Regional Oncology Hospital or the Osh Regional Unified Clinical Hospital, where there is a hematology department. This would eliminate the need for trips to Bishkek.
"This is not just a matter of numbers and documents, but a matter of human life," the deputy emphasized, urging for a protocol directive to be given to the Ministry of Health to address this issue.
Additionally, she touched upon the issue of medical provision in the village of Tüzbel in the Jalpak-Tash rural district of the Uzgen region. In a village with over 7,800 residents, the local hospital is in an emergency state, and only nurses are working, with no doctors available.
Egenberdieva noted that emergency patients are left without necessary supervision at night, and they have to travel to the nearest village of Kurshab, which takes about 45 minutes. This is especially complicated in winter when additional difficulties arise.
